Education
About Us
Working with TipRanks
Follow Us
Omeros Corporation (OMER)
:OMER
OMER Stock Chart & Stats
$7.52
-$0.23(-2.31%)
At close: 4:00 PM EST
$7.52
-$0.23(-2.31%)
Day’s Range― - ―
52-Week Range$2.95 - $13.60
Previous CloseN/A
Volume193.12K
Average Volume (3M)6.30M
Market Cap
$582.80M
Enterprise Value$599.04M
Total Cash (Recent Filing)$36.09M
Total Debt (Recent Filing)$191.61M
Price to Earnings (P/E)―
Beta0.94
Next Earnings
Mar 03, 2026EPS Estimate
-0.52Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.47
Shares Outstanding70,900,460
10 Day Avg. Volume2,077,952
30 Day Avg. Volume6,302,146
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)-3.15
Price to Sales (P/S)0.00
P/FCF Ratio-3.86
Enterprise Value/Market Cap1.03
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-56.54
Enterprise Value/Ebitda-5.24
Forecast
1Y Price Target
$13.11Price Target Upside74.34% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Financial StabilityNovo Nordisk is in-licensing the global rights to OMS-906 as part of a potential total $2.1B agreement, which includes a $240MM upfront payment that allows OMER to address near-term debt obligations and provides operational runway for over 12 months.
Licensing AgreementOMER and Novo Nordisk announced an asset purchase and license agreement for OMER's zaltenibart in clinical development for rare blood and kidney disorders.
Narsoplimab Approval ProspectsNarsoplimab demonstrates a differentiated clinical profile and reinforces its potential to become the first approved therapy for transplant-associated thrombotic microangiopathy (TA-TMA).
Bears Say
FDA Approval SkepticismSkepticism for narsoplimab approval has increased recently with the unveiling of details on the historical external controls and recent FDA CRLs on programs using historical controls for data comparisons.
Financial InstabilityThere is an urgent financial overhang that the company needs to address, indicating financial instability.
Regulatory Approval ChallengesThere is skepticism of FDA approval of narsoplimab given the limited clinical dataset from open-label trials and the lack of new clinical data to support a positive regulatory decision.
Omeros News
OMER FAQ
What was Omeros Corporation’s price range in the past 12 months?
Omeros Corporation lowest stock price was $2.95 and its highest was $13.60 in the past 12 months.
What is Omeros Corporation’s market cap?
Omeros Corporation’s market cap is $582.80M.
When is Omeros Corporation’s upcoming earnings report date?
Omeros Corporation’s upcoming earnings report date is Mar 03, 2026 which is in 93 days.
How were Omeros Corporation’s earnings last quarter?
Omeros Corporation released its earnings results on Nov 13, 2025. The company reported -$0.47 earnings per share for the quarter, missing the consensus estimate of -$0.447 by -$0.023.
Is Omeros Corporation overvalued?
According to Wall Street analysts Omeros Corporation’s price is currently Undervalued.
Does Omeros Corporation pay dividends?
Omeros Corporation does not currently pay dividends.
What is Omeros Corporation’s EPS estimate?
Omeros Corporation’s EPS estimate is -0.52.
How many shares outstanding does Omeros Corporation have?
Omeros Corporation has 70,900,460 shares outstanding.
What happened to Omeros Corporation’s price movement after its last earnings report?
Omeros Corporation reported an EPS of -$0.47 in its last earnings report, missing expectations of -$0.447. Following the earnings report the stock price went up 25.318%.
Which hedge fund is a major shareholder of Omeros Corporation?
Currently, no hedge funds are holding shares in OMER
Omeros Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$13.11 (74.34% Upside)
$13.11 (74.34% Upside)
Blogger Sentiment
Neutral
OMER Sentiment 50%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 61.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.4%
Last 30 Days ▲ 10.1%
Last 30 Days ▲ 10.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
36.48%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-40.73%
Trailing 12-Months
Company Description
Omeros Corporation
Omeros Corporation (OMER) is a biopharmaceutical company focused on discovering, developing, and commercializing small-molecule and protein therapeutics for various medical conditions. The company operates primarily in the field of inflammation, coagulopathies, and central nervous system disorders. Omeros' lead product, Omidria, is used in cataract and lens replacement surgery to prevent intraoperative miosis and reduce postoperative ocular pain. Additionally, the company is engaged in multiple clinical-stage development programs targeting conditions such as complement-mediated diseases and addiction.
OMER Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Omeros Corporation's earnings call highlighted a strategic partnership with Novo Nordisk, significant progress in regulatory approvals for Yartemlia, and improved financial positioning through debt repayment. Despite reporting a higher net loss and cash burn, the company's robust pipeline and upcoming milestones position it for potential future success.View all OMER earnings summariesOMER Stock 12 Month Forecast
Average Price Target
$13.11
▲(74.34% Upside)
Technical Analysis
Aldeyra Therapeutics
―
Abeona Therapeutics
―
I-MAB
―
Foghorn Therapeutics
―
Neumora Therapeutics, Inc.
―
Ownership Overview
3.46% Insiders
7.24% Mutual Funds
9.31% Other Institutional Investors
71.15% Public Companies and Individual Investors